
Physician who leads GV's life science investments in therapeutics, diagnostics and medical devices.
| Aera Therapeutics: Akin Akinc on Building a Biotech Company and Breaking Barriers in Genomic Medicine | GV | Article | 2023-07-19 |
| Prime Medicine’s IPO: Moving Gene Editing Forward | GV | Article | 2022-10-24 |
| Ben Robbins is Our Newest General Partner | GV | Article | 2022-07-28 |
| Welcoming Biotech Executive Cathy Friedman to GV | GV | Article | 2022-01-06 |
| Prime Medicine’s Keith Gottesdiener on the Promise of Gene Editing | GV | Article | 2021-07-13 |
| Biotech Leader Dan Lynch Joins the GV Life Sciences Team | GV | Article | 2021-04-26 |
| Leyden Labs’ Unconventional Approach to Pandemic Preparedness with Intranasal Medicine | GV | Article | 2021-03-25 |
| Dr. Richard Scheller on Scientific Rigor, Genetics, and the Evolution of Drug Development | GV | Article | 2020-12-11 |
| Richard Scheller on COVID-19 Vaccine Breakthroughs | GV | Article | 2020-12-08 |
| Encoded Therapeutics and the Drive to End Pediatric Epilepsy | GV | Article | 2020-07-22 |